Smrke Alannah, Tam Yuen B, Anderson Peter M, Jones Robin L, Huang Paul H
BC Cancer, Vancouver, BC V5Z 4E6, Canada.
Sarcoma Unit, Royal Marsden Hospital, 203 Fulham Road, London SW36JJ, UK.
J Bone Oncol. 2021 Oct 22;31:100400. doi: 10.1016/j.jbo.2021.100400. eCollection 2021 Dec.
Osteosarcoma is a rare, primary tumour of bone. Curative treatment consists of multi-agent chemotherapy and complete surgical resection. Despite the use of multi-agent chemotherapy, the risk of recurrence is high. Survival outcomes for patients with osteosarcoma have not changed since the 1980's. Based on biologic rationale, there has been interest in adding immunotherapies to upfront curative intent chemotherapy, including mifamurtide (a macrophage activator) and interferon. However, results to date have been disappointing. In the metastatic setting, checkpoint inhibitors alone have not proven effective. Ongoing translational work is needed to further understand which patients may benefit from immune-oncology approaches with standard cytotoxic chemotherapy.
骨肉瘤是一种罕见的原发性骨肿瘤。根治性治疗包括多药化疗和完整的手术切除。尽管使用了多药化疗，但复发风险仍然很高。自20世纪80年代以来，骨肉瘤患者的生存结果并未得到改善。基于生物学原理，人们对在初始根治性化疗中加入免疫疗法产生了兴趣，包括米伐木肽（一种巨噬细胞激活剂）和干扰素。然而，迄今为止的结果令人失望。在转移性情况下，单独使用检查点抑制剂尚未证明有效。需要持续开展转化研究工作，以进一步了解哪些患者可能从免疫肿瘤学方法联合标准细胞毒性化疗中获益。
